University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Joanna Phillips, MD, PhD

Joanna Phillips, MD, PhD

Assistant Professor, Neurological Surgery and Pathology; Co-Director UCSF Brain Tumor SPORE Biorepository

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

I am an Assistant Professor in the UCSF Departments of Neurological Surgery and Pathology, Director of the UCSF Brain Tumor Research Center Tissue Biorepository and Histology Core, Co-Director of the UCSF Neuropathology BTRC Biomarkers Laboratory, Co-Director of the UCSF Brain Tumor SPORE Biorepository, and Director of the Biospecimen and Biostatistics Core for a UCSF brain tumor-focused Program Project (P01). I received my MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine in 2002, and I have over ten years of experience working in cancer and neuropathology. My research interests focus on studying how factors in the brain tumor microenvironment, including the extracellular matrix and immune cells, influence tumor development and invasion. I am the PI of an NINDS-funded R01 and an NCI-funded U01, and have published over 70 publications related to the development and therapy of brain tumors.

Education

Cornell University, Ithaca, NY, BS, 05/1994, Biology/Biochemistry
University of Pennsylvania, Philadelphia, PA, PhD, 05/2001, Neuroscience
University of Pennsylvania, Philadelphia, PA, MD, 05/2002, Medicine
University of Washington, Seattle, WA, Residency, 2002-2004, Anatomic Pathology
University of California SF, San Francisco, CA, Fellow, 2004-2006, Neuropathology


Professional Experience

  • 2002–2004
    Resident, Department of Anatomic Pathology, University of Washington
  • 2004–2006
    Clinical Fellow, Department of Pathology, University of California San Francisco
  • 2006-2008
    Postdoctoral Fellow, Mentor: Zena Werb, Ph.D., Department of Anatomy, University of California San Francisco
  • 2008–2010
    Clinical Instructor, Department of Pathology, University of California San Francisco
  • 2009-Present
    UCSF Brain Tumor Research Center Tissue Bank, Neuropathologist
  • 2010-Present
    Assistant Professor Neurological Surgery and Pathology, University of California, San Francisco
  • 2010-Present
    Co-Director UCSF Brain Tumor SPORE Biorepository
  • 2012-Present
    UCSF Helen Diller Family Comprehensive Cancer Center, Member
  • 2012-Present
    Society for Glycobiology

Honors & Awards

  • 1993-94
    Cornell University, Hughes Scholars Program
  • 1994
    Cornell University, graduated with honors and distinction in Biology
  • 1999
    American Society for Virology travel award
  • 2001
    Stuart Mudd Award in Microbiology, University of Pennsylvania School of Medicine
  • 2005
    Moore Award for best paper on clinico-pathologic correlation, annual meeting of American Association of Neuropathologists
  • 2006
    Nominated UCSF School of Medicine Essential Teaching Award
  • 2006
    Young Pathologist Fellowship, American Society for Investigative Pathology, Experimental Biology annual meeting
  • 2006-08
    American Brain Tumor Association: Susan Resnick Fisher/American Brain Tumor Association Fellowship
  • 2008
    Rubinstein Award, best paper on neuro-oncology, annual meeting of American Association of Neuropathologists
  • 2010
    Aspen Cancer Conference Fellow
  • 2012
    Second place, Moore Award, Best paper on clinic-pathological correlation, annual meeting of American Association of Neuropathologists
  • 2013
    Nominated UCSF School of Medicine Essential Core Teaching Award

Selected Publications

  1. Goode B, Joseph NM, Stevers M, Van Ziffle J, Onodera C, Talevich E, Grenert JP, Yeh I, Bastian BC, Phillips JJ, Garg K, Rabban JT, Zaloudek C, Solomon DA. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol. 2017 Nov 17.
    View on PubMed
  2. Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol. 2017 Oct 25.
    View on PubMed
  3. Lopez GY, Oberheim Bush NA, Phillips JJ, Bouffard JP, Moshel YA, Jaeckle K, Kleinschmidt-DeMasters BK, Rosenblum MK, Perry A, Solomon DA. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Acta Neuropathol. 2017 Oct 23.
    View on PubMed
  4. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 Sep 15.
    View on PubMed
  5. Tran VM, Wade A, McKinney A, Chen K, Lindberg OR, Engler JR, Persson AI, Phillips JJ. Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion. Mol Cancer Res. 2017 Aug 04.
    View on PubMed
  6. Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Sci Rep. 2017 Mar 22; 7:44792.
    View on PubMed
  7. Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell. 2017 Mar 13; 31(3):424-435.
    View on PubMed
  8. Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 02 01; 19(2):242-251.
    View on PubMed
  9. Neill E, Luks T, Dayal M, Phillips JJ, Perry A, Jalbert LE, Cha S, Molinaro A, Chang SM, Nelson SJ. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol. 2017 Mar; 132(1):171-179.
    View on PubMed
  10. Miroshnikova YA, Mouw JK, Barnes JM, Pickup MW, Lakins JN, Kim Y, Lobo K, Persson AI, Reis GF, McKnight TR, Holland EC, Phillips JJ, Weaver VM. Tissue mechanics promote IDH1-dependent HIF1a-tenascin C feedback to regulate glioblastoma aggression. Nat Cell Biol. 2016 Dec; 18(12):1336-1345.
    View on PubMed
  11. Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD, Garcia PA, Rabinovici GD, Coppola G, Geschwind DH, Petrucelli L, Miller BL, Seeley WW. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016 Dec; 139(Pt 12):3202-3216.
    View on PubMed
  12. Ge X, Gong H, Dumas K, Litwin J, Phillips JJ, Waisfisz Q, Weiss MM, Hendriks Y, Stuurman KE, Nelson SF, Grody WW, Lee H, Kwok PY, Shieh JT. Missense-depleted regions in population exomes implicate ras superfamily nucleotide-binding protein alteration in patients with brain malformation. NPJ Genom Med. 2016; 1.
    View on PubMed
  13. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 Dec; 130(3):543-552.
    View on PubMed
  14. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Jin LW, Bastian BC, Bollen AW, Perry A, Nicolaides T, Solomon DA, Shieh JT. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathol. 2016 Nov; 132(5):757-760.
    View on PubMed
  15. Wood MD, Reis GF, Reuss DE, Phillips JJ. Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence. J Neuropathol Exp Neurol. 2016 Oct; 75(10):925-935.
    View on PubMed
  16. Mukherjee J, Ohba S, See WL, Phillips JJ, Molinaro AM, Pieper RO. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. Int J Cancer. 2016 Jul 01; 139(1):99-111.
    View on PubMed
  17. Jalbert LE, Neill E, Phillips JJ, Lupo JM, Olson MP, Molinaro AM, Berger MS, Chang SM, Nelson SJ. Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro Oncol. 2016 Aug; 18(8):1169-79.
    View on PubMed
  18. Radoul M, Chaumeil MM, Eriksson P, Wang AS, Phillips JJ, Ronen SM. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. Mol Cancer Ther. 2016 May; 15(5):1113-22.
    View on PubMed
  19. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Brain Pathol. 2016 Sep; 26(5):569-80.
    View on PubMed
  20. Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Res. 2015 Dec 15; 75(24):5355-66.
    View on PubMed

Go to UCSF Profiles, powered by CTSI